Video Experimental Relacionado
Updated: Sep 9, 2025
07:50
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
2.8K
Actualización sobre los eventos tromboembólicos después de la vacunación contra la COVID-19
Theocharis Anastasiou1, Elias Sanidas1, Thekla Lytra2
1Department of Cardiology, "Laiko" General Hospital, 11527 Athens, Greece.
Vaccines
|August 28, 2025
Resumen
Las vacunas contra la COVID-19, especialmente los tipos de vectores adenovirales, están vinculadas a eventos tromboembólicos raros como el VITT. Sin embargo, los beneficios superan los riesgos, y las vacunas de ARNm muestran tasas más bajas de eventos trombóticos.
Área de la Ciencia:
- Inmunología
- Vacunas y vacunas
- Investigación de la trombosis
Sus antecedentes:
- La vacunación contra el COVID-19 ha planteado preocupaciones con respecto a los eventos tromboembólicos, particularmente con las vacunas de vectores adenovirales.
- Las complicaciones tromboembólicas, incluyendo VITT, ATE y VTE, son raras pero documentadas después de la vacunación.
Objetivo del estudio:
- Revisar la aparición y las características de las complicaciones tromboembólicas y renales después de la vacunación contra la COVID-19.
- Comparar el riesgo trombótico asociado a las diferentes plataformas de vacunación.
- Hacer hincapié en las estrategias de gestión actuales y el perfil de beneficio-riesgo general de las vacunas contra la COVID-19.
Principales métodos:
- Revisión de la literatura de estudios sobre las vacunas contra la COVID-19 y los eventos tromboembólicos.
- Análisis de los casos notificados de VITT, VTE, ATE y complicaciones renales.
- Análisis comparativo del riesgo trombótico entre las vacunas de vector adenoviral y de ARNm.
Principales resultados:
- Los eventos tromboembólicos (VTE, ATE, VITT) y las complicaciones renales raras son poco comunes después de la vacunación contra COVID-19.
- Los factores de riesgo incluyen la edad, el sexo, el tipo de vacuna y las comorbilidades.
- Las vacunas de ARNm demuestran un riesgo significativamente menor de eventos trombóticos graves en comparación con las vacunas de vectores adenovirales.
Conclusiones:
- A pesar de las complicaciones trombóticas raras, las vacunas contra la COVID-19 son cruciales para prevenir enfermedades graves y mortalidad.
- La evaluación de riesgos individualizada y la gestión rápida son fundamentales.
- Se prefieren las vacunas de ARNm debido a un perfil de riesgo trombótico más bajo.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:51Vaccinations
45.3K
Overview
45.3K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
01:30Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889